<code id='DFD132D883'></code><style id='DFD132D883'></style>
    • <acronym id='DFD132D883'></acronym>
      <center id='DFD132D883'><center id='DFD132D883'><tfoot id='DFD132D883'></tfoot></center><abbr id='DFD132D883'><dir id='DFD132D883'><tfoot id='DFD132D883'></tfoot><noframes id='DFD132D883'>

    • <optgroup id='DFD132D883'><strike id='DFD132D883'><sup id='DFD132D883'></sup></strike><code id='DFD132D883'></code></optgroup>
        1. <b id='DFD132D883'><label id='DFD132D883'><select id='DFD132D883'><dt id='DFD132D883'><span id='DFD132D883'></span></dt></select></label></b><u id='DFD132D883'></u>
          <i id='DFD132D883'><strike id='DFD132D883'><tt id='DFD132D883'><pre id='DFD132D883'></pre></tt></strike></i>

          leisure time

          leisure time

          author:explore    Page View:263
          Matts Take Column Illustration
          Molly Ferguson for STAT

          American medicine is a tragic paradox. An example: Cancer patients are likely dying as a result of drug shortages that occurred partly because generic chemotherapies have been allowed to become too cheap. At the same time, other patients are suffering, and perhaps dying, because the financial burden brought on by the expensive medicines they need is too high.

          Sit with that like a terrible Zen koan: Medicines are both too cheap and too expensive.

          advertisement

          How is that possible? A lot of it goes back to the 1984 Hatch-Waxman Act, which set up the ecosystem that determines the process by which drugs go from being expensive brands to cheap generics in the U.S.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more
          Ed Silverman on new gene therapies, biosimilars, coffee, and more
          Ed Silverman on new gene therapies, biosimilars, coffee, and more

          STAT'sEdSilvermanonstageattheSTATBreakthroughSummitin2023.SarahGonzalezforSTATIn2023,STATlaunchedabr

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          In utero gene editing: an explainer

          AnnaYeo/STATRecentlyapprovedgenetherapiesofferpatientsone-time,potentiallycurativetreatmentsforgenet